Trial Profile
Pharmacokinetics of Abacavir Once Daily vs. Twice Daily and Lamivudine Once Daily vs. Twice Daily in HIV-infected Thai Children
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Abacavir (Primary) ; Lamivudine (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 20 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov
- 10 Aug 2012 New trial record